Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 30Breast Neoplasms 26Neoplasms 24Neoplasm Metastasis 24Triple Negative Breast Neoplasms 21Parkinson Disease 4, Autosomal Dominant Lewy Body 10Lung Neoplasms 9Melanoma 8Stomach Neoplasms 7Carcinoma, Pancreatic Ductal 7Adenocarcinoma 7Ovarian Neoplasms 6Colorectal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Esophageal Neoplasms 4Digestive System Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Rectal Neoplasms 3Pancreatic Diseases 3Neoplasms by Site 3Lymphoma, Non-Hodgkin 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Endocrine Gland Neoplasms 3Digestive System Diseases 3

Interventions

pembrolizumab 2napabucasin 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1Biological Therapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thymus Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT01325441 2023-11-15

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
565 enrolled 17 charts

Neoplasms, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡